← All stories · business

MarketWatch

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Friday, July 31, 2026

Novo Nordisk's stock declined on Friday following the company's announcement of a Phase 3 trial failure.

Original reporting: https://www.marketwatch.com/story/novo-nordisks-stock-slumps-after-failed-trial-adding-to-the-companys-woes-202419cd?mod=mw_rss_topstories

Next story

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years→